Michael A. McManus, Jr., CEO of Misonix, Selected As A Top Micro-Cap CEO By ExecRank

Feb 20, 2015, 10:56 ET from Misonix, Inc.

FARMINGDALE, N.Y., Feb. 20, 2015 /PRNewswire/ -- Misonix, Inc. (Nasdaq: MSON), an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, announced today that Chief Executive Officer Michael A. McManus, Jr. has been selected as a Top Chief Executive Officer at a Micro-Cap Company for 2014 by ExecRank. The rankings are based on statistical and algorithmic analysis of executive and company performance and are the result of over three years of research and feedback from evaluation committees and top Chief Executives.

"This recognition is a tribute to the entire Misonix team for its dedication, creativity and boundless energy in successfully addressing the challenges that face our industry while driving operational growth and shareholder value," said Mr. McManus. "We continue to gain traction on our strategic plan in the U.S. and throughout the international markets in which we compete. We are excited with the opportunities ahead in the coming years, and I am proud to accept this honor on behalf of the employees and the loyal shareholders of Misonix."

ExecRank screened more than 10,000 Chief Executive Officers in the United States. Only the very best are awarded the distinction of being a part of ExecRank's Top Chief Executive Officers Ranking for 2014. As always, there was a premium on experience and track record when considering our rankings, but also on CEOs who took bold steps to help their companies maintain and grow market share in evolving industries. ExecRank weighed heavily the recommendations provided by the Boards of Directors of our finalists.

About ExecRank

ExecRank Inc. is a research and advisory firm founded in 2010 and the leading source for executive rankings and C-Suite performance reports. Based on statistical and algorithmic analysis of executive and company performance, this research is used to make intelligent and informed decisions at the highest tier of human capital and corporate strategy for clients ranging from venture backed startups to large cap public companies. ExecRank rankings reach over 5 million readers a year in the United States alone given our partnerships with leading publishers, web sites, trade shows and more.

For the complete rankings, please visit www.ExecRank.com or at: http://execrank.com/2014-rankings/top-ceos-driving-shareholder-value-micro-cap-companies/.

About Misonix, Inc.

Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

Safe Harbor Statement

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

Investor Relations Contacts:

Misonix Contact:

Lytham Partners, LLC

Richard Zaremba

Robert Blum, Joe Dorame, Joe Diaz






SOURCE Misonix, Inc.